Nonsteroidal Anti-inflammatory Drug (NSAID) Tolerance After Biological Therapy in Patients With NSAID-Exacerbated Respiratory Disease: A Randomized Comparative Trial

after 6 months of each biological therapy (intragroup comparisons). As exploratory outcomes, we compared NSAID tolerance between biological therapies (intergroup RESULTS: A total of 38 subjects were included; 9 received omalizumab. There was an increase in the concentration needed to produce a reaction during ASA-OCT with omalizumab (P < .001) and dupilumab (P 1/4 .004) but not with mepolizumab and frequency of NSAID tolerance (omalizumab 60%, dupilumab increased ASA tolerance, whereas mepolizumab and benralizu

Automated summary

After 6 months of biological therapy, it was found that the tolerance to NSAIDs increased with omalizumab and dupilumab, but not with mepolizumab and benralizumab.